Compare GGR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGR | SERA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Taiwan | United States |
| Employees | 1416 | N/A |
| Industry | Auto Manufacturing | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 75.2M |
| IPO Year | N/A | 2021 |
| Metric | GGR | SERA |
|---|---|---|
| Price | $3.90 | $1.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.0K | ★ 18.9K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $5.07 | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.24 | $1.37 |
| 52 Week High | $6.21 | $4.09 |
| Indicator | GGR | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 35.80 |
| Support Level | $3.63 | N/A |
| Resistance Level | $4.25 | $2.41 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 25.00 | 17.39 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.